The Israel-based company posted a loss of -$974 million on sales of $6.49 billion for the 3 months ended Dec. 31, for bottom-line loss of -296% on sales growth of 33% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were $1.38, ahead of consensus on The Street, where analysts were looking for sales of $6.24 billion.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva Pharmaceutical beats Q4 earnings, sales estimates appeared first on MassDevice.
from MassDevice http://ift.tt/2kkhAC3
Cap comentari:
Publica un comentari a l'entrada